Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Burn Baby Burn
View:
Post by biggdogg on Mar 14, 2024 1:57pm

Burn Baby Burn

This comment is what I am most interested in after reviewing the news.  The preparation of a carbon production Revenue Sharing Agreement is underway to exploit carbon captured and leverage the cash flow generated by carbon production technology at Voyageur's future pharmaceutical manufacturing facility. Voyageur is evaluating several existing pharmaceutical facilities, to enable the vertical integration of its pharmaceutical projects and align with its vision of integrating sustainability into pharmaceutical production
They are looking at pharmaceutical plants to buy? They must have financing to do this? Carbon revenue sharing? This means an entirely new revenue stream from a hydrocarbon generator energy. If I where in Vegas I would be betting on a large carbon farm being attached to the Voy project. According the GPTchat, 2.68 kg of CO2 from 1 litre of diesel. 0.2729 kg of carbon in 1 kg of CO2. 1 L diesel x .2729=0.73kg/L carbon. If they are burning 400L/hr, they are creating 292.5kg/hr carbon x 24hr =7 tonnes a day x 365=2,555 tonnes a year. This is going to get really damn good folks; I think this is going to blow the markets socks off when it becomes a reality. Fullerene is very valuable, currently $200/gram = $200,000,000 a tonne. If you just use hypotetically $100K/tonne they will be producing $255.5M a year of this new carbon material. If Voy gets just 10% of this revenue, the stock is going to Mars. This is based on 100% efficiency, which will never be the case.
 
Comment by postie1 on Mar 14, 2024 4:12pm
biggdogg, I like your positivity and man do I have a lot of reasons to hope you are right and the sooner the better!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1